MSD and Moderna have kicked off another phase 3 trial of their personalised cancer vaccine V940 used alongside MSD's PD-1 inhibitor Keytruda, this time focusing on patients with earlier-stage ...
MSD is reported to have been negotiating with Swiss biotech MoonLake Immunotherapeutics over a takeover deal – estimated to be worth more than $3 billion – according to media reports. The Financial ...
After 10 weeks of training at IMG Academy in Florida, 13 athletes from the International Player Pathway program will take the field for a workout in front of NFL scouts. IPP consultant Scott Pioli ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback